Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRay Therapeutics, Inc.

About this trial

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.

The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.

The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records

Best-corrected visual acuity between 20/200 to HM in at least one eye.

Reasonably fluent in English or Spanish

Disqualifiers

Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.

Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol

Current pregnancy as reported by patient

Trial population

Patients with moderate to profound vision impairment diagnosed with retinitis pigmentosa or other retinal dystrophies.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

25 Participants
are grouped into 2 trial groups
Group A: Retinitis Pigmentosa
Group B: Other Retinal Dystrophies

Trial outcomes

Primary outcomes

1

Operational feasibility of testing moderate to profound vision impaired patients with various retinal dystrophies on a battery of visual assessments

Determining how many patients in the visual range 20/200 - HM (depending upon indication) can perform specific tests of visual function with a measurable score.

Time frame
3 months

Secondary outcomes

1

To quantify patient-based measurement properties of each test modality (for the purposes of endpoint qualification)

Test-rest reliability on the same visit or on two different testing sessions on different days including determination of significant learning effects of other scoring variables that impact variability.

Time frame
2 years
2

To quantify assessor-based measurement properties of each test modality (for the purposes of endpoint qualification)

Intra- and inter-grader variability for scoring of tests by test graders/raters. Assessments incorporating independent graders/raters will be assessed for within session and across session scoring reliability to ensure consistent methods.

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.